http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#Head
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#assertion
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#provenance
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#pubinfo
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#assertion
http://purl.obolibrary.org/obo/DOID_5419
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_5419
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01224
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association
http://www.w3.org/2000/01/rdf-schema#label
seroquel xr is an atypical antipsychotic indicated for the treatment of schizophrenia 1 1 adults efficacy was established with seroquel xr in one 6 week and one maintenance trial in patients with schizophrenia as well as in three 6 week trials with seroquel in patients with schizophrenia 14 1 acute treatment of manic or mixed episodes associated with bipolar i disorder both as monotherapy and as an adjunct to lithium or divalproex 1 2 adults efficacy was established with seroquel xr in one 3 week trial in patients with manic or mixed episodes associated with bipolar i disorder as well as two 12 week monotherapy trials and one 3 week adjunctive trial with seroquel in patients with manic episodes associated with bipolar i disorder 14 2 acute treatment of depressive episodes associated with bipolar disorder 1 2 adults efficacy was established with seroquel xr in one 8 week trial in patients with bipolar i or ii disorder as well as two 8 week trials with seroquel in patients with bipolar i or ii disorder 14 2 maintenance treatment of bipolar i disorder as an adjunct to lithium or divalproex 1 2 adults efficacy was established with seroquel in two maintenance trials in patients with bipolar i disorder 14 2 adjunctive treatment of major depressive disorder mdd 1 3 adults efficacy as an adjunct to antidepressants was established in two 6 week trials in patients with mdd who had an inadequate response to an antidepressant alone 14 3 seroquel xr is indicated for the treatment of schizophrenia the efficacy of seroquel xr in schizophrenia was established in one 6 week and one maintenance trial in adults with schizophrenia as well by extrapolation from three 6 week trials in adults with schizophrenia treated with seroquel see clinical studies seroquel xr is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder both as monotherapy and as an adjunct to lithium or divalproex the efficacy of seroquel xr in manic or mixed episodes of bipolar i disorder was established in one 3 week trial in adults with manic or mixed episodes associated with bipolar i disorder as well by extrapolation from two 12 week monotherapy and one 3 week adjunctive trial in adults with manic episodes associated with bipolar i disorder treated with seroquel see clinical studies seroquel xr is indicated for the acute treatment of depressive episodes associated with bipolar disorder the efficacy of seroquel xr was established in one 8 week trial in adults with bipolar i or ii disorder as well as extrapolation from two 8 week trials in adults with bipolar i or ii disorder treated with seroquel see clinical studies seroquel xr is indicated for the maintenance treatment of bipolar i disorder as an adjunct to lithium or divalproex efficacy was extrapolated from two maintenance trials in adults with bipolar i disorder treated with seroquel the effectiveness of monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials see clinical studies seroquel xr is indicated for use as adjunctive therapy to antidepressants for the treatment of mdd the efficacy of seroquel xr as adjunctive therapy to antidepressants in mdd was established in two 6 week trials in adults with mdd who had an inadequate response to antidepressant treatment see clinical studies
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB01224
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#provenance
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#pubinfo
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#sig
http://purl.org/nanopub/x/hasSignature
P8jfgkiIpRZeMDXhKrcvfV+VkFTJk/0huU+lXWmZn2lPfgc8O+3viHV5lstMrJfpGYgQSonpW0OEAlfdf4SXyZBEKa2kJkBaO7//iXejd/nMoIO6SP+yyYtitqiWUPzXLLgseUo0r4y5RfrmSIWa/83YF9m+s83muq96Yzk6nDs=
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo
http://purl.org/dc/terms/created
2021-06-13T16:05:50.956+02:00
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs